Blood Res 2019; 54(2):
Published online June 30, 2019
https://doi.org/10.5045/br.2019.54.2.153
© The Korean Society of Hematology
Correspondence to : Naohiro Sekiguchi
Hematology Division, National Hospital Organization Disaster Medical Center, 3256 Midori-cho, Tachikawa, Tokyo 190-0014, Japan
E-mail: nao26nao26@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Survival curve. (A) Progression-free survival (PFS). The median PFS of half-dose R-CHOP therapy was not reached, and the estimated 2-year PFS was 72% and 3-year PFS was 64%. The estimated 3-year second PFS by a bendamustine-containing regimen was 89%. (B) Overall survival (OS). The estimated 3-year OS was 96%.
Swimmer plot for 25 patients who received half-dose R-CHOP therapy. Nine patients developed refractory disease or progression and 3 patients received third-line therapy.
Table 1 Summary of responses to each regimen, survival, and drug prices.
a)Ibrutinib is not approved in Japan for WM. b)Data relapsed/refractory WM.
Abbreviations: R, rituximab; DRC, dexamethasone, R, cyclophosphamide; R-CHOP, R, cyclophosphamide, hydroxyl-doxorubicin, vincristine, prednisone; BDR, bortezomib, dexamethasone, R; ORR, overall response rate; JPY, japanese yen; PFS, progression-free survival; TTF, time to treatment failure; TTP, time to progression; PD, progressive disease; NA, not applicable; NR, not reached.
Blood Res 2019; 54(2): 153-156
Published online June 30, 2019 https://doi.org/10.5045/br.2019.54.2.153
Copyright © The Korean Society of Hematology.
Naohiro Sekiguchi1,2, Airi Hamano3, Tomoko Kitagawa2, Kenichi Ito1, Kazuhiko Hirano4, Kazuaki Yamada4
1Hematology Division, 2Clinical Research Division, 3Pharmaceutical Division, 4Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Correspondence to:Naohiro Sekiguchi
Hematology Division, National Hospital Organization Disaster Medical Center, 3256 Midori-cho, Tachikawa, Tokyo 190-0014, Japan
E-mail: nao26nao26@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Survival curve. (A) Progression-free survival (PFS). The median PFS of half-dose R-CHOP therapy was not reached, and the estimated 2-year PFS was 72% and 3-year PFS was 64%. The estimated 3-year second PFS by a bendamustine-containing regimen was 89%. (B) Overall survival (OS). The estimated 3-year OS was 96%.
Swimmer plot for 25 patients who received half-dose R-CHOP therapy. Nine patients developed refractory disease or progression and 3 patients received third-line therapy.
Table 1 . Summary of responses to each regimen, survival, and drug prices..
a)Ibrutinib is not approved in Japan for WM. b)Data relapsed/refractory WM..
Abbreviations: R, rituximab; DRC, dexamethasone, R, cyclophosphamide; R-CHOP, R, cyclophosphamide, hydroxyl-doxorubicin, vincristine, prednisone; BDR, bortezomib, dexamethasone, R; ORR, overall response rate; JPY, japanese yen; PFS, progression-free survival; TTF, time to treatment failure; TTP, time to progression; PD, progressive disease; NA, not applicable; NR, not reached..
Survival curve. (A) Progression-free survival (PFS). The median PFS of half-dose R-CHOP therapy was not reached, and the estimated 2-year PFS was 72% and 3-year PFS was 64%. The estimated 3-year second PFS by a bendamustine-containing regimen was 89%. (B) Overall survival (OS). The estimated 3-year OS was 96%.
|@|~(^,^)~|@|Swimmer plot for 25 patients who received half-dose R-CHOP therapy. Nine patients developed refractory disease or progression and 3 patients received third-line therapy.